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Over the past decades, the human life span has dramatically increased, and therefore,
a steady increase in diseases associated with age (such as Alzheimer’s disease and
Parkinson’s disease) is expected. In these neurodegenerative diseases, there is a
cognitive decline and memory loss, which accompany increased systemic inflammation,
the inflamm-aging, and the insulin resistance. Despite numerous studies of age-related
pathologies, data on the contribution of brain insulin resistance and innate immunity
components to aging are insufficient. Recently, much research has been focused on the
consequences of nutrients and adiposity- and nutrient-related signals in brain aging and
cognitive decline. Moreover, given the role of metainflammation in neurodegeneration,
lifestyle interventions such as calorie restriction may be an effective way to break the
vicious cycle of metainflammation and have a role in social behavior. The various effects
of calorie restriction on metainflammation, insulin resistance, and neurodegeneration
have been described. Less attention has been paid to the social determinants of aging
and the possible mechanism by which calorie restriction might influence social behavior.
The purpose of this review is to discuss current knowledge in the interdisciplinary field
of geroscience—immunosenescence, inflamm-aging, and metainflammation—which
makes a significant contribution to aging. A substantial part of the review is devoted
to frontiers in the brain insulin resistance in relation to neuroinflammation. In addition,
we summarize new data on potential mechanisms of calorie restriction that influence
as a lifestyle intervention on the social brain. This knowledge can be used to initiate
successful aging and slow the onset of neurodegenerative diseases.
Keywords: aging, inflammation, inflammasome, metaflammasome, insulin resistance, Alzheimer’s disease,
anti-inflammatory strategies, calorie restriction
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INTRODUCTION
It is a known fact that over the past decades, human life
expectancy has greatly increased (Costantini et al., 2018). As
a result, the population is aging, and this determines the
development of geriatric medicine. Since aging is the main
risk for the development of age-associated diseases, the field
of geriatrics and geroscience has been developing very actively
recently. The main goal of studies is to avoid age-related diseases
before it is too late. Recently, the number of publications on anti-
aging technologies and interventions has been increasing. This
topic is certainly very popular not only in the medical community
but also in society (Scapagnini et al., 2016).
Aging may be a complex process that happens under the
influence of genetic, epigenetic, and environmental factors.
Changes in an aging organism occur at the molecular, cellular,
and tissue levels (Khan et al., 2017). In this regard, the
question naturally arises on what factors possibly influence it.
The most promising and effective approaches are nutritional
strategies, physical activity, and hormone therapy (Scapagnini
et al., 2016). In addition, these approaches can be used
not only as anti-aging strategies but also as preventive
directions. Preventive technologies will slow down aging
and have a greater impact on quality of life than disease-
specific approaches.
In order to understand the basis for development the
directions of preventive and anti-age medicine, it is necessary to
understand what basic pathological processes underlie the aging
process. Some of these processes that determine aging include
inflammation, cellular senescence, and senescence-associated
secretory phenotype (SASP) development, altered glucose
tolerance, and insulin resistance (IR) following dysregulated
nutrient sensing and impaired cell–cell communication (De
Souto Barreto et al., 2020). All these pathophysiological processes
underlie age-associated neurodegenerative disorders.
It is predicted over the subsequent years that the incidence of
age-related neurodegenerative diseases will increase dramatically.
One of the most important factors in brain aging is the extremely
high energy demand of neurons for maintaining neuronal work
and preserving mental abilities (Davinelli et al., 2016).
With age, there is an increase in systemic inflammation,
the inflamm-aging, and peripheral immunosenescence.
Due to reciprocal interactions between the nervous and
immune systems, chronic aseptic inflammation within central
nervous system (CNS), called neuro-inflamm-aging, develops.
Immunosenescence and inflamm-aging accompany brain aging
and the loss of mental, cognitive, and other complex behaviors
characteristic of Alzheimer’s disease (AD) and Parkinson’s
disease (PD) (Khan et al., 2017; Costantini et al., 2018).
Recently, much research has been focused on the
consequences of nutrients, and adiposity- and nutrient-
related signals in brain aging and cognitive decline. Previously,
it has been shown that insulin signaling affects the molecular
cascades that underlie hippocampal functions, cognition, and
memory (Spinelli et al., 2019). Our previous results have shown
that a significant contribution to the development of brain IR
is caused by neuroinflammation due to the overproduction of
proinflammatory cytokines, astroglial and microglial activation,
and disruption of the processes of reparative neurogenesis
(Komleva et al., 2018).
The purpose of this review is to discuss current knowledge in
interdisciplinary field of geroscience—immunosenescence,
inflamm-aging, and metainflammation—which make a
significant contribution to aging. A substantial part of the
review is devoted to frontiers in the brain IR in relation to
neuroinflammation. In addition, in this article, we summarize
new data on potential mechanisms of calorie restriction (CR)
influence as a lifestyle intervention on the social brain. This
knowledge can be used to initiate successful aging and slow the





Immunosenescence is a phenomenon of irreversible loss of the
ability to divide, as a result of which damage to the immune
defense is observed, which contributes to the progression of
susceptibility to disease in the elderly. Immunosenescence occurs
when the ability to respond to new antigens is reduced (Pawelec,
2017). In addition, a variety of factors affect the progression
of immunosenescence—genetics, environment, lifestyle, and
nutrition—leading to infections and progression of disease
pathology (Figure 1) (Costantini et al., 2018).
Franceschi et al. (2000) first used the term “inflamm-aging,”
proposing a hypothesis based on a series of observations
showing that aging of many organisms, including humans,
is accompanied by an increase in the level of inflammatory
markers in the blood, cells, and tissues. This is chronic,
sterile, not associated with the presence of an infectious
agent, and primarily due to endogenous signals, or subclinical
(asymptomatic), mild, or basal inflammation, which is associated
with aging. Already today, more and more studies indicate
that “inflammatory” aging or inflammation associated with age
is a risk factor for many chronic non-communicable diseases,
such as cardiovascular (coronary heart disease and arterial
hypertension), metabolic [diabetes mellitus 2 type (T2D)],
musculoskeletal (osteoarthritis, osteoporosis, and sarcopenia),
neurological (depression, dementia, and AD), and hematologic
(malignant neoplasms and anemia) diseases, which leads to
adverse effects on human health (Giunta et al., 2008). Many
researchers agree that the number of nosologies is not limited to
this list (Deleidi et al., 2015; Pawelec, 2017). The approaches for
the treatment of diseases in which inflammation predominates
in the pathogenesis may include, in addition to limiting caloric
intake and increasing physical activity, the use of drugs. The
drug action is aimed at limiting it by interfering with the
processes of intracellular and extracellular signaling at different
stages, and not only involves the impact on the main clinical
manifestations or targets (blood pressure, cholesterol, blood
sugar, etc.) (Zotkin et al., 2020).
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FIGURE 1 | The interaction of factors initiating the development of metabolic damage, inflammation, and inflamm-aging. The aging process and age-related disease
can be accompanied with central and peripheral insulin resistance, inflammation, and accumulation of senescent cells. FFAs, free fatty acids.
Alzheimer’s Disease and
Neuroinflammation
AD is a fatal neurodegenerative disorder that is pathologically
defined by extensive neuronal loss and the accumulation of
intracellular neurofibrillary tangles (NFTs) and extracellular
amyloid plaques in the brain. Studies since the discovery of
amyloid beta (Aβ) and tau protein have provided detailed
information on molecular pathological events, but little is known
about the causes of AD, as well as about the possible effective
treatment of this pathology (Silva et al., 2019; Tiwari et al., 2019).
It is well known that the risk of late-onset AD is partially
due to genetics. In 2019, the results of a large meta-analysis of
associations across the genome of clinically diagnosed late-onset
AD were published. Currently, 25 risk loci are affected, five of
which were identified in the latest study. Another confirmation
of the contribution of the immune system to the late onset
of AD confirms that the neurological and immune-mediated
disease haplotype HLA-DR15 (human leukocyte antigen) is a risk
factor for AD. In addition to tau-binding proteins and amyloid
precursor protein (APP) metabolism, pathway analysis includes
immunity and lipid metabolism, which are also associated with
late onset of AD (Kunkle et al., 2019).
Newly discovered evidence proposes that inflammation is an
important feature of AD, diabetes mellitus, and other pathologies;
and it is believed that this process plays an important role in
the pathogenesis of these syndromes. Therefore, understanding
the interactions between the nervous system and the immune
system may be key to preventing or delaying the onset of most
diseases of the CNS. Neuroinflammation is an important part of
the brain’s defense mechanisms against a variety of pathological
agents, such as infections and injuries, and includes both the
formation of soluble factors and the activation of specialized cells
that are mobilized to respond and restore the brain’s normal
physiology. Neuroinflammation is characterized by neuronal
death in certain areas of the CNS (Figure 2) (Salmina et al., 2015;
Calsolaro and Edison, 2016).
In AD, central events seem to combine the inflammasome,
NF-κB pathway, and the microglial activation by a variety
of factors, including Aβ and proinflammatory cytokines
(Harms et al., 2015; Rea et al., 2018). Aβ in the brain
microenvironment causes the glial activation that leads to
microgliosis and astrocytosis around pathological proteins.
Thus, glial cells are chronically activated in the brain before
the onset of AD, which is associated with the development of
chronic inflammation and contributes to the pathogenesis
of AD. In the AD brain, microgliosis and astrocytosis
because of the presence of senile plaques and NFTs can be
detected immunohistochemically, and these glial cells exhibit
pathologically specific morphology. Although the degree of
gliosis correlates with cortical thickness and neurodegeneration,
the role of various glial cells in neurodegenerative processes
remains unknown (Saito and Saido, 2018).
Microglia, the main immune cells of the brain’s innate
immunity, perform movements similar to macrophages to
remove pathogens and protect neurons from various factors. At
the same time, microglial cells secrete reactive oxygen species
(ROS) and nitric oxide, which are neurotoxic. They also release
proinflammatory cytokines and chemokines in response to
danger signals. Dysregulation of microglial activity is associated
with the pathogenesis of AD during aging (Salmina et al., 2015;
Clayton et al., 2017). Triggering receptor expressed on myeloid
cells-2 (TREM2) plays an important role in supporting microglial
cell survival. Previously, it was shown that TREM2 promotes
microglial clustering around fibrillar Aβ plaques in AD mouse
model and postmortem human brain sections (Ulrich et al.,
2017). Furthermore, TREM2 is a Aβ receptor that mediates
microglial function and removal of Aβ (Zhao et al., 2018). An
increase in soluble TREM2 fragments in cerebrospinal fluid
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FIGURE 2 | The immune–brain communication. The main functions of immune system are cell communications, tissue homeostasis, protecting against pathogens
and various substances, and eliminating pathological cells. During aging, increased systemic inflammation leads to impaired homeostasis and could result to
cognitive deficit. NLRP3, NLRP3 inflammasome; SASP, senescence-associated secretory phenotype; BBB, blood–brain barrier.
indicates coincidence with markers of neuronal damage and
onset of clinical dementia in AD (Ulrich et al., 2017).
It should be noted that recent human positron emission
tomography (Aβ-PET) data indicate that Aβ deposition
begins years before memory impairment and cognitive decline
(Hatashita and Wakebe, 2019). Given the fact that Aβ acts as
strong damage-associated molecular patterns (DAMPs), it seems
that the interval between early accumulation of Aβ and later signs
of disease progression, such as tau pathology and brain atrophy,
is influenced by innate immune responses (Table 1). One of the
canonical pathways of this Aβ-induced innate immune response
is the activation of the NOD-like receptor (NLR) family, a pyrin
domain-containing 3 (NLRP3) inflammation, which has been
the subject of intense research (Heneka et al., 2018) (Figure 3).
Studies have shown that Aβ oligomers can trigger the
expression of the NLRP3 inflammasome and thus promote
inflammation and intensify association between T2D and AD
(Rea et al., 2018). Inflammasome is involved in the progression
of metabolic syndrome due to impaired adipose tissue sensitivity.
It has been conclusively demonstrated that obesity triggers
NLRP3 activation and that secreted IL-1β that impairs insulin
signaling, which contributes to IR in mice (Mori et al., 2011; Rea
et al., 2018). Another study found that obesity was associated
with NLRP3 activation in adipose tissue (Mori et al., 2011;
Vandanmagsar et al., 2011; Rea et al., 2018).
The role of NLRP3 inflammasomes in the pathogenesis of
obesity has been supported by data showing that Nlrp3−/−
and Asc−/− knockout mice are protected from obesity and
IR induced by a high-fat diet. In addition, NLRP3 activation
by inflammasomes/caspase-1 appears to be a key regulator of
adipocyte differentiation and directs adipocytes to an insulin-
resistant phenotype (Stienstra et al., 2010).
Consequently, CR and weight loss in obese diabetic subjects
decrease the expression of the Nlrp3 and IL-1 genes in adipocytes,
improving insulin sensitivity (Vandanmagsar et al., 2011).
However, some studies have failed to find an association between
NLRP3 inflammasome formation and obesity or IR (Nishimoto
et al., 2016). Understanding the molecular mechanisms of
chronic inflammation remains a major medical problem
(Nishimoto et al., 2016; Rheinheimer et al., 2017). Thus, further
research is required to understand the relationship between
NLRP3 inflammasome formation and IR.
Moreover, the inflammasome pathway is activated by a variety
of intracellular processes and associated with increased age and
age-related diseases. Both the inflammatory pathway and the
senescent cell-related SASP activate the inflammasome through
the NF-κB and IL-α cascade, causing the inflammatory response
and cytokine production that delays resolution and healing
(Chien et al., 2011; Mori et al., 2011; Rea et al., 2018).
Therefore, caspase-1 or inflammasome inhibitors have been
proposed as novel treatments for pathologies associated with
aging and metabolism deterioration (Stienstra et al., 2010;
Kanbay et al., 2019).
METABOLIC HALLMARKS OF AGING
AND THEIR ROLE IN THE COGNITIVE
RESERVE
One of the most urgent tasks of modern gerontology is
the search for various pathogenic factors that worsen the
health and well-being of the elderly. Loss of function over
time is distinctive for aging. Usually, the deterioration
of the physical and mental condition occurs gradually.
Incidentally, it is still not known whether this diminishment
could be a result of physiological or pathological processes
(Akintola and van Heemst, 2015).
Cognitive reserve is the determining factor in the difference
between physiological and pathological brain aging. Cognitive
reserve is related to the brain’s ability to maintain cognitive
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TABLE 1 | Damage-associated molecular patterns (DAMPs), their receptors and molecular action in insulin resistance and Alzheimer’s disease.
DAMP Receptors or sensors Molecular action and effects References
High mobility group box 1
(HMGB1) (alarmin)
RAGE, TLR4 Signal to the NF-κB signaling pathway and thus contributes to the inflammatory
responses in type 2 diabetes mellitus, in the genesis and pathophysiology of IR
and neurodegeneration.
Gonelevue et al.,
2018; Paudel et al.,
2020
Aβ (amyloid) TLR4, TLR2, NLRP3,
CD36, CD14 receptor
Aβ activates the NLRP1 and NLRP3 inflammasomes. The oligomers can disturb
the functions of K+ channels, decreasing the intracellular K+ concentration and
thus activating caspase-1. Increasing K+ efflux with valinomycin led to activated
caspase-1 and IL-1β secretion from neurons.
Aβ can also activate microglial cells in the brain through interaction with the
surface receptor CD36, which induces the formation of a TLR2–TLR6






Chromogranin A (CGA) (an acidic
protein localized in secretory
vesicles)
TLR4, CD14, or class A
scavenger receptor
The stimulation of target receptors promotes the uptake of Aβ and
phagolysosome formation. Upon lysosomal rupture, cathepsin B release is




ATP P2 × 7R (an ATP-gated ion
channel supporting Na+
and Ca2+ influx into and
K+ efflux out of the cell)
The decrease in intracellular K+ leads to P2 × 7R-mediated NLRP3
inflammasome formation. Together with IL-1β release, NLRP3 inflammasome
activation in the brain through the P2 × 7 receptor induces an increase of tau
secretion in exosomes and its subsequent transmission to neurons.
Muñoz-Planillo





lipid- signaling molecule that is
formed from serine and 2 fatty
acids)
NLRP3 Ceramide can act as an endogenous signal to caspase-1 cleavage and IL-1β
secretion
Shin et al., 2015;
Venegas and
Heneka, 2019
S100 RAGE Stimulate cell proliferation and migration and inhibit of apoptosis and
differentiation, which participate in neurodegenerative processes. RAGE





mt-DNA and cf-DNA TLR9
AIM2
Induce the release of interferon type 1 and TNF-α.
Exogenous mtDNA fragments induced TLR9-mediated NF-κB activation in
primary muscle cells. mtDNA increased TLR9 content in muscle cells.
When cf-DNA binds to TLR, signaling occurs through MyD88, which leads to a
type I IFN response.
When cf-DNA binds to AIM2, caspase-1 is activated, and subsequently, IL-1β is
released.





HSPs—heat shock proteins PRRs (pattern recognition
receptor).
TLR2 and TLR4
Interaction with receptors leads to the induction of inflammatory cytokines such




Homocysteine (Hcy) NLRP3 Activation of the inflammasome with the subsequent release of interleukins. Hcy
mediates the development of insulin resistance.
Smith et al., 2018;
Zhang et al., 2018
Glucose NLRP3 Induction of IL-1β secretion followed by increased apoptosis triggered by Fas
via NF-κB and JNK and/or inhibiting insulin signaling.
Shin et al., 2015
IAPP [islet amyloid polypeptide
(IAPP)–amylin]
NLRP3, CD36, and RAGE IAPP has cytotoxic effects; assembly of the inflammasome leads to the
formation of mature IL-1β.
Fawver et al., 2014;
Shin et al., 2015
FFAs and their metabolites
(palmitate)
NLRP3, TLR4 The production of inflammatory cytokines through activation of TLR and NLRP3
contributes to the development of insulin resistance by suppressing insulin
signaling.
Shin et al., 2015
function despite being constantly under the influence of stressors
and degenerative events associated with aging and the AD
development. It is known that hippocampal neurogenesis is a
lifelong process of continuous inclusion of functionally active
new neurons into neuronal circuits. Accordingly, neurogenesis
in the adult hippocampus is increasingly seen as a key
factor in the sustainability of the cognitive reserve (Dainikova
and Pizova, 2014). In addition, it was determined that the
decisive factor in determining the resistance of nerve tissue
to neurodegeneration is age-related decline in glial function
and metabolic coupling. Thus, impairment of neuroglia and
cell metabolism promotes the transition from physiological to
pathological aging (Verkhratsky et al., 2015, 2020).
Risk factors that have been considered in relation to
brain aging include metabolic disorders. The aging process
of the brain can be accompanied with impaired glucose
metabolism or decreased glucose supply to the brain. Moreover,
brain IR has been associated with an increased risk of
both cognitive decline and dementia, including AD and
vascular dementia (Hughes and Craft, 2016; Yin et al., 2016;
Baranowska-Bik and Bik, 2017) (Figure 1).
Currently, research has made significant progress in
understanding the pathogenesis of AD but, unfortunately,
without any disease-modifying therapeutics or proven
prevention strategies. One of the most relevant and promising
areas in terms of therapeutic effects is the study of brain
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FIGURE 3 | NLRP3 inflammasome and metaflammasome activation in response to DAMPs. In the brain, activation of toll-like receptors leads to the assembly of
NLRP3 inflammasomes and the maturation and release of IL-1β. Through cytokine receptors, kinases are activated—components of metaflammasome—JNK and
IKK. This leads to impaired insulin signaling and the development of insulin resistance, which leads to dysfunction of synapses and the development of
neurodegeneration. Aβ, amyloid beta; Akt, protein kinase B; ASC, apoptosis-related speck-caspase recruitment domain; DAMPs, damage-associated molecular
patterns; IDE, insulin degrading enzyme; IKK, IkBa kinase; IRS, insulin receptor substrate; JNK, c-Jun N-terminal kinases; NLRP3, NOD-like receptor pyrin domain-3
inflammasome; PKC, protein kinase C; PKR, double-stranded RNA-dependent protein kinase; Ras/ERK, kinase regulated by extracellular signals; TLR, toll-like
receptors.
metabolism. The leading opinion postulates that glucose
metabolism is reduced in almost every neurological and
psychiatric condition (Mosconi et al., 2009; Bélanger et al., 2011;
Neth and Craft, 2017).
Brain Insulin, Glucose, and Other Energy
Sources for Thoughts During Aging
Until now, the production of insulin in the brain remains a
controversial issue. There is a lot of conflicting evidence about
the production of insulin in brain structures and cell types.
The initial hypothesis was that insulin is able to cross the
blood–brain barrier (BBB) through a saturable transport system.
However, this mechanism is limited and ineffective. Later, data
appeared on the possible production of insulin in the brain.
Thus, the expression of mRNA and insulin protein was found
in the hippocampus, olfactory bulb, striatum, hypothalamus, and
entorhinal and prefrontal cortices (Mehran et al., 2012). Insulin
secretion has also been reported in cultured astrocytes (Takano
et al., 2018). In a recent study, the authors describe the presence of
not only insulin mRNA but also the protein itself in the epithelial
layer of the choroid plexus of mice and humans, along with
proteins associated with the processing and secretion of insulin
(Mazucanti et al., 2019).
Since the stability of the cognitive reserve is largely determined
by neurogenesis, the study of metabolic trophic factors that
influence this process is important. Insulin at moderate
concentrations is known to play a neurotrophic role. Insulin
has a pivotal role in the brain development, functioning of
neurogenic niches, and aging. Activation of the insulin/IGF-I
(insulin-like growth factor) signaling pathway regulates the exit
of neuroblasts from the quiescence state. This signaling cascade,
insulin and IGF-I, has been shown to promote neurogenesis by
modulating proliferation, differentiation, and survival of neural
stem cells (NSCs) (rev. in Spinelli et al., 2019). In healthy
metabolic conditions, acute increases in insulin levels have a
valuable effect on cognition. Nevertheless, chronically elevated
insulin significantly reduces the level of its mediated effects
(Neumann et al., 2008). Moreover, chronic hyperactivation of the
insulin/IGF-I pathway can cause premature depletion of the stem
cell pool (Spinelli et al., 2019). In contrast, high insulin levels
may be associated with increased Aβ deposition in the brain,
as insulin and Aβ compete for the same enzyme that provides
their clearance, namely, the insulin-degrading enzyme (Hölscher,
2019). Thus, insulin can have a trophic or deleterious effect
on neurogenesis (Spinelli et al., 2019). This conclusion can be
confirmed by studies demonstrating impaired learning in animals
with a model of type 2 diabetes mellitus (T2DM), as well as the
observed cognitive deficit in clinical studies among patients with
this pathology (Zilliox et al., 2016).
Recently, the term “type 3 diabetes mellitus” has often been
used to denote AD, since the pathological events accompanying
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this pathology are pathogenetically associated with central IR
(Kandimalla et al., 2017). Aβ suppresses insulin expression in
astrocytes (Pitt et al., 2017; Spinelli et al., 2019). These data show
bi-directional changes between impaired brain insulin signaling
and Aβ deposition in AD. According to these results, local IR and
changes in central glucose metabolism may be considered as early
markers for the diagnosis of AD (Hölscher, 2019).
It was shown that central glucose hypometabolism can be
detected decades before the clinical onset of AD (Mosconi
et al., 2009; Sperling et al., 2011; Neth and Craft, 2017).
However, in the last few years, it is becoming increasingly
obvious as a condition of reactive or compensatory glucose
hypermetabolism in neurologic diseases as an initial reaction
to trauma and developing pathological processes (Ashraf et al.,
2015; Neth and Craft, 2017). According to Neth and Craft
(2017), a glucose hypermetabolism could be a temporary solution
to the injury problem with a permanent reduction in glucose
utilization. If additional data confirm the occurrence of an
initial increase and a final decrease in glucose metabolism
in the brain, then this shift can be visualized at an early
stage (before the onset of clinical symptoms) and work to
prevent the pathology. This hypermetabolic glucose shift at
the early stages is likely complemented by increased use of
other fuels as well. As the disease progresses, a bioenergy
shift may occur due to a decrease in glucose dependence
and an increase in the use of alternative energy sources
(Neth and Craft, 2017).
As it has already been mentioned, the most preferred energy
substrate for the brain, except the prolonged fasting, is glucose.
For normal functioning of the brain, a constant supply of glucose
is necessary. In small concentrations, glycogen was also found
in the brain, which is stored in astrocytes. Glycogen provides
lactate as an energy source for neurons through monocarboxylate
transporters to support neural functions such as hippocampal-
regulated memory formation and learning (Rich et al., 2019).
Under conditions of reduced glucose intake, ketone bodies,
mainly formed as a result of fatty acid (FA) oxidation, are an
alternative main source of energy. In addition, FAs and their
metabolites are capable of influencing many brain functions.
This also allows them to be considered as potential targets for
pharmacological and/or dietary interventions in certain brain
pathologies (Romano et al., 2017).
Nevertheless, glucose is of the greatest importance as a
brain energy substrate, and therefore, disturbances in glucose
metabolism have significant consequences on the functioning of
the brain. Decreased hippocampal volumes have been described
in elderly with impaired glucose tolerance. It accompanied
with a lower cognitive test performance. Similarly, another
study confirmed that patients with higher fasting glucose and
glycosylated hemoglobin experienced decreased memory and
learning ability (Grabenhenrich, 2014). Glucose hypometabolism
was most obviously recorded in the frontal, parietal, and temporal
cortices (Tondo et al., 2020). This suggests that IR affects similar
areas of the brain as in AD, supporting the notion that central
IR may contribute to neurodegeneration. Moreover, diabetes has
been repeatedly shown to be a strong predictor of cognitive
dysfunction in the elderly (Kong et al., 2018).
Cognitive decline is not limited to impairments in learning
and memory; there are other impairments as well. Brain IR has
been confirmed to be associated with decreased task processing
speed, cognitive flexibility, and motor skills. Current evidence
confirmed that IR should be considered as an pivotal risk factor
for the progression of cognitive dysfunction (Moheet et al., 2015).
Thus, clinical work and experimental studies in animals
propose that IR has destructive effects on cognitive functions,
in particular on learning and memory. Therefore, it becomes
the principal aim to study the metabolic pathways and
their association with the progression of AD and other
neurodegenerative disorders (Spinelli et al., 2019).
Brain Insulin Resistance in the
Pathological Aging
Changes in brain insulin signaling, and in particular in
the hippocampus, can alter molecular pathways involved in
synaptic plasticity and neurogenesis in adults, thereby leading
to a decrease in cognitive reserve, an increased risk of
neurodegeneration, and a shortened life span (Epel, 2020).
Long-term persistent excess of nutrients is the cause of
stress acceleration of aging. However, an excess of nutrients
causes hyperactivation of insulin signaling and leads to
desensitization of IR-dependent molecular cascades. Because
of this influence, the brain stops responding to insulin and
eliminates both the metabolic and cognitive effects of this
hormone (Spinelli et al., 2019).
IR makes it difficult for cells to maintain energy homeostasis.
The brain in AD neurodegeneration is accompanied by changes
similar to those observed in peripheral tissues in diabetes
mellitus, including metabolic stress and neuroinflammation
(Talbot et al., 2012). Thus, it can be assumed that such
mechanisms explain IR in T2DM and impair central insulin
transduction in patients with AD. Significant similarities between
neuropathogenic mechanisms are induced by Aβ oligomers and
cause the loss of neurons and synapses, as well as mechanisms
associated with peripheral IR in diabetes (Craft, 2012).
Many explanations have been proposed for the impaired
insulin transduction in the AD brain. One of them is
decreased extracellular insulin assessed in cerebrospinal fluid,
decreased total or cell surface of insulin receptor expression,
and decreased affinity of insulin receptors for insulin (Talbot,
2014). The deficiency of extracellular insulin in the AD brain
remains unclear and identified the opposite results obtained in
cerebrospinal fluid (Molina et al., 2002). Similarly, deficits in
total insulin receptors in AD brain tissues were not found in
studies using age-matched controls, and cell fractionation did
not reveal deficiencies in insulin receptor levels on the cell
surface. Although the binding of insulin to the insulin receptor
may be reduced in the brain tissue in AD, insulin still manages
to activate the catalytic domain of the insulin receptor at a
level of 71–74% of normal levels even in the hippocampal
formation in AD. As noted above, a significantly greater decrease
in insulin sensitivity is observed already after binding to the
insulin receptor in the brain in AD. In the hippocampus, which
is responsible for memory and learning, insulin activated only
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10% of the normal level of insulin receptor substrate (IRS)
(Talbot et al., 2012).
Thus, the most likely cause of decreased insulin signaling in
the brain in AD is IR due to dysfunctional IRS-1. This appears
to reflect Aβ-induced secretion of proinflammatory cytokines
by glial cells. Among the early changes in AD, there is an
increased solubility of Aβ, the monomers of which combine to
form oligomers, which can later assemble into fibrils and form
amyloid plaques (Sengupta et al., 2016). Also at the AD onset,
Aβ oligomers activate microglia, which leads to the secretion of
proinflammatory cytokines such as IL-1, IL-6, and tumor necrosis
factor α (TNF-α) (Hemonnot et al., 2019). Such activation of
microglia may play a key role in the AD pathogenesis, given the
recent discovery that disabling a gene in AD model encoding
a microglial receptor (i.e., NOD-like receptor 3) and perceiving
inflammatory pathogens, including Aβ, prevent the development
of AD and cognitive abnormalities that usually occur in this
AD animal model (Heneka et al., 2013). Through neuronal
receptors, microglial IL-1, IL-6, and TNF-α activate serine kinases
IRS-1, known as IkBa kinase (IKK), C-Jun N-terminal kinase
(JNK), and extracellular signal-regulated kinase (Erk2) (Talbot
and Wang, 2014). Thus, Aβ oligomers injected into neuronal
cultures or into the cerebral ventricles markedly increase the
phosphorylation of IRS-1 serine (IRS-1 pS) at several sites,
namely, S312, S616, and/or S636 (S307, S612, and S632 in rodents’
Erk2) (Talbot and Wang, 2014).
Elevated neural IRS-1 pSer is significant in the cortex and
hippocampal formation in AD and, apparently, is the main cause
of IRS-1 dysfunction in AD (Tanokashira et al., 2019). The most
common cause of IR is inhibition of downstream signaling due
to serine phosphorylation of the IRS1 (Boucher et al., 2014).
Similar changes occur in the AD brain. Insulin activation of IRS-
1 is consistently decreased in tissues with significantly increased
levels of IRS-1 pS616 and IRS-1 pS636. These molecules may
act as potential markers of central IR (Talbot et al., 2012; Talbot
and Wang, 2014). As expected, the levels of these candidate
biomarkers correlate significantly with the Aβ deposition and are
associated with cognitive decline (Kong et al., 2018).
This may explain crossroad peripheral IR due to obesity
and/or diabetes mellitus and brain IR in AD (Liu et al., 2011).
Obesity and T2DM are, in fact, risk factors for AD and are
associated with increased vascular proinflammatory cytokines
(Pugazhenthi et al., 2017). With the development of AD, the
impaired integrity of the BBB promotes the penetration of
cytokines. They, in turn, activate IRS-1 serine kinases in the same
way as cytokines obtained from microglia (Ferreira et al., 2018).
Frontiers in Insulin Resistance Markers
The relationship between IR and AD may be enhanced due
to a common etiology leading to an increased risk of AD
(Spinelli et al., 2019). IR is a potentially modifiable risk factor
for AD; in this regard, early diagnosis of IR remains highly
relevant. Previous research has relied on measurements of
systemic IR based on blood glucose and insulin values, such
as the Homeostatic Model of Insulin Resistance (HOMA-IR)
assessment (da Silva et al., 2019). Peripheral and central IR
overlap to some extent, and this may explain why associations
between HOMA-IR and glucose hypometabolism in the brain
have been observed. Currently, a variety of proteins have been
isolated that are consistently significantly related to IR and
AD pathology. They are discoidin, CUB, and LCCL domain-
containing protein 2 (DCBLD2); Ephrin-B2 (ENFB2); ciliary
neurotrophic factor receptor subunit alpha (CNTFR); neuronal
growth regulator 1 (NEGR1); leucine-rich repeat-containing
protein 4B (LRRC4B); and SLIT and NTRK-like protein 4
(SLITRK4). However, a search for markers specific to central IR
is also required (Westwood et al., 2017).
For these reasons, in recent years, research has focused
on assessing glucose metabolism in the brain and analyzing
extracellular brain vesicles extracted from blood as biomarkers
of IR and early phase of cognitive decline. In a study in patients
with IR, but without loss of cognitive functions, IR was associated
with hypometabolism in the hippocampus and higher levels of
blood pressure biomarkers in the cerebrospinal fluid (Westwood
et al., 2017). Cerebral glucose metabolism is closely related to
neuronal activity, and a decrease in the cerebral metabolic rate
for glucose (CMRglc) is one of the main hallmarks of AD. In vivo
imaging using 2-[18F]fluoro-2-deoxy-D-glucose PET (FDG-PET)
demonstrates a consistent and progressive decrease in CMRglc in
patients with AD. A decrease in CMRglc in preclinical stages of
AD, with mild cognitive impairment (MCI) was also indicated,
as well as in carriers of the allele of apolipoprotein E-epsilon-4, a
strong genetic risk factor of AD (Mosconi et al., 2008).
In a recent study, Mullins et al. (2017) demonstrated that
pSer312-IRS-1 (which stimulates uncoupling of IRS-1 and leads
to its degradation) and p-panTyr-IRS-1 (which promotes insulin-
stimulated responses) are biomarkers of AD. Based on these
data, a methodology for the isolation of exosomes from plasma
was developed, followed by immunoprecipitation against the cell
surface adhesion protein L1-CAM to enrich neural origins. It
was demonstrated that pathogenic and signal peptides in plasma
exosomes expressing L1-CAM/NCAM effectively distinguish
between AD and control group and can predict the diagnosis of
the disease. In addition, it was confirmed that the peripheral IR
is separated from the brain IR that occurs in AD (Mullins et al.,
2017; Kapogiannis et al., 2019; Spinelli et al., 2019). These data
indicate the presence of IR of the brain in patients with AD and,
to a lesser extent, in people with diabetes (Mullins et al., 2017;
Spinelli et al., 2019).
Neuroinflammation and Brain Insulin
Resistance
Inflammation is a feature of diabetes mellitus and AD, and
it is believed that this process plays an important role in
the pathogenesis of these two pathologies. Inflammation is an
important part of the body’s defense mechanisms against many
pathological agents, such as infections and trauma, and includes
both the formation of soluble factors and the activation of specific
cells that are mobilized to respond and maintain the normal
physiology and homeostasis (Chatterjee and Mudher, 2018).
It is believed that similar inflammatory processes occur
in the CNS and periphery. The presence of inflammatory
markers in AD in the brain tissue, including increased levels
of cytokines/chemokines, which accompany with gliosis, was
confirmed in many studies (Cao, 2015). In addition, an increase
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of inflammatory mediators in the blood, such as TNF-α, IL-
6, and IL-1β, was observed in patients suffering from AD (Ng
et al., 2018). Moreover, increased production of proinflammatory
cytokines in adipose tissue is a key feature of the pathogenesis of
metabolic disorders. A recent study has shown that an elevated
level of TNF-α expressed in adipose tissue of obese individuals
is the reason of peripheral IR. Therefore, in both the central
and peripheral tissues, uncontrolled or chronic inflammation
accompanies IR (Saltiel and Olefsky, 2017). Interestingly,
inflammation also underlies hypothalamic dysfunction in obesity
(Samodien et al., 2019). New evidence indicates that it is the
inflammation and stress of the endoplasmic reticulum that
are critical pathogenetic events in the central and peripheral
IR in metabolic disorders (Arruda et al., 2011). In an obese
and diabetic animal model, the neuroinflammation, especially
through activation of TNF-α and the IkBa kinase (IKK)-b/nuclear
factor-kB pathway, is a principal mechanism underlying the
disease pathogenesis (Milanski et al., 2009). Consequently, the
pathology of the hippocampus in AD and the pathology of the
hypothalamus in obesity have common pathogenetic pathways
associated with inflammation (De Felice and Ferreira, 2014).
Our own data have shown the protective phenotype of Nlrp3
knockout mice in the development of brain IR (Chernykh
et al., 2018). Using an experimental approach to modeling
AD, we investigated new molecular mechanisms of insulin
signaling dysregulation in the amygdala in association with
neuroinflammation and emotional disorders. It has been
established that experimental AD is accompanied by impaired
expression and functional activity of molecules–components of
insulin-mediated signaling pathways and the development of IR
together with up-regulation of neuroinflammation in the brain
amygdala. This cascade of pathological reactions is reflected
in emotional behavior disorder. NLRP3-dependent mechanisms
have been demonstrated in the basolateral amygdala in normal
conditions and during the development of neurodegeneration. It
has been experimentally proven that preventing the development
of local IR by blocking NLRP3 inflammasomes should be
considered an approach to correcting BIR and emotional
disorders in AD. The studied molecular mechanisms linking
the development of local IR with neuroinflammation (with the
participation of pIRS, GLUT4, IRAP, and NLRP3) and impaired
cognitive and emotional spheres open up new possibilities for the
prevention and correction of neurodegeneration in AD.
Thus, suppression of neuroinflammation by preventing the
expression of NLRP3 inflammasomes in Nlrp3-knockout mice
has a protective role in the development of AD, accompanied
by IR, due to modulation of the expression of pIRS-Ser and
downstream of insulin signaling cascade (Gorina et al., 2019).
Activation of Proinflammatory Factors
and Signaling Pathways in a Cell Upon
Damage to Insulin Signaling in Neurons
in Alzheimer’s Disease
In peripheral IR, impaired TNF-α signaling results in JNK
activation (Chen et al., 2015). Activation of the TNFa/JNK
pathological pathway is associated with the main inflammatory
and stress-signaling mechanisms, including tension of the
endoplasmic reticulum and activation of stress kinases IKK (IkBa
kinase) and PKR (double-stranded RNA-dependent protein
kinase) (Nakamura et al., 2010). In T2DM, high levels of TNF-
α initiate serine phosphorylation of IRS-1 by stress kinases,
blocking insulin signaling (Nakamura et al., 2010). TNF-α levels
increase in microvessels of the brain and cerebrospinal fluid in
AD (Ruan et al., 2009). Initial information that impaired insulin
signaling in neurons in AD is associated with proinflammatory
signaling was based on the fact that oligomers of Aβ induce
inhibition of IRS-1 through TNF-a/JNK activation (Bomfim
et al., 2012). These ideas were confirmed, and it was shown
that common mechanisms underlie damaged peripheral insulin
transduction in diabetes mellitus and central local IR in the AD
brain. Namely, it was shown that IKK and PKR were increased
in AD in the brain, and they mediate the inhibition of IRS-1
in hippocampal neurons induced by oligomers of Aβ (Lourenco
et al., 2013). IKK mediates neuronal inhibition of IRS-1 by Aβ
oligomers (Bomfim et al., 2012).
METAFLAMMATION AND
METAFLAMMASOME
As already described, assembly of the multiprotein complex
inflammasome occurs not only in neurodegenerative diseases
but also in metabolic disorders. The terms “metabolic
inflammasomes” or “metaflammasomes” encompass metabolic
disorders and the inflammation they cause. In other words,
metaflammasome is a cascade of a signaling response in a cell
caused by DAMPs followed by a metabolic pathway response
and cytokine release (Table 1 and Figure 3) (Kanbay et al., 2019;
Kuryłowicz and Koźniewski, 2020).
The expression of the four main components of the
metaflammasome complex has been confirmed in the human
brain. It includes phosphorylated forms of IKKβ, IRS1, JNK, and
PKR (Taga et al., 2017).
C-Jun N-terminal kinases (JNKs) play an important role
in a wide range of different stress-induced pathways. Thus,
they are involved in neuronal cell death, migration, neuronal
plasticity, autophagy, regeneration, metabolism, and regulation
of cellular aging. Various stressors, including cytokines, ROS,
growth factors, and Aβ oligomers, initiate the JNK signaling
pathway. The role of JNK has been confirmed in studies of
the relationship between neuronal death in AD and amyloid
plaques. JNKs have been shown to increase Aβ production and
are involved in the maturation and development of NFTs. In
addition, it is currently considered a promising area of study of
potential JNK inhibitors as a potential target for the treatment of
neurodegenerative changes in AD (Yarza et al., 2016).
Studies have experimentally confirmed that low levels of
JNK in T2DM are not accompanied by the development of
cognitive impairments, including dementia. Conversely, a high
level of C-Jun N-terminal kinases expression was recorded in
patients with dementia and comorbid AD. In this regard, it has
been convincingly demonstrated that JNK inhibition in the liver
improves insulin signaling and reduces glucose tolerance. Kinase
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inhibition leads to a decrease in obesity and an increase in insulin
sensitivity, while with the development of obesity, a pathological
increase in expression is noted (rev. in Taga et al., 2017).
Another component of the so-called metaflammasome, which
is involved in the regulation of inflammation, is IKKβ. IKKβ has
a neuroprotective function by inhibiting neuronal NF-κB. This
in turn protects neurons from Aβ and oxidative stress (Liu et al.,
2017; Taga et al., 2017).
A recent study investigated the relationship of these four
kinases. The data on the strength of the relationship between the
components of the metaflammasome are compelling. Therefore,
it was shown that there is no relationship between IKKβ and
JNK kinases in the absence of dementia. At the same time,
with the progression of AD, an inverse relationship is observed
between IKKβ and JNK. There is no connection between IKKβ
and IRS1 and PKR. This shows the special role of the relationship
between the components of the metaflammasome, depending on
the state, the presence of pathology, and the brain environment
(Taga et al., 2017).
Another of the kinases of the so-called metaflammasome
complex is a proapoptotic enzyme—eukaryotic initiation factor
2α kinase 2 (PKR). PKR inhibits translation and participates
in cellular signaling, which leads to brain damage in AD and
impaired memory consolidation. Aβ results in the activation
of PKR and its accumulation in degenerating neurons. PKR
modulates Aβ synthesis through the induction of beta-site
APP-cleaving enzyme 1 (BACE 1). An elevated level of PKR
was observed in the cerebrospinal fluid in AD patients and
patients with an MCI. PKR activation leads to downstream
cascade resulting in TNFα and IL1-β production. It was also
shown experimentally that PKR inhibits molecular processes of
memory consolidation. This kinase is also currently considered
as a potential target for inhibition, can reduce neuronal
death, and can facilitate cognitive decline in neurodegeneration
(Hugon et al., 2017).
It was reported by Taga et al. (2017) that high expression
of IRS1 and PKR is associated with cognitive impairment but
not dementia. There are suggestions that the components of
the metaflammasome can be activated precisely in the early
stages of AD or in MCIs, which also makes these kinases
promising for use as marker molecules for early diagnosis of
degenerative events. This is confirmed by experimental animal
studies, where after the intervention of a high-fat diet with the
development of IR, an increase in IRS1 in the mice hippocampus
was noted, which was accompanied by a deficit in spatial working
memory due to postsynaptic impairment (Arnold et al., 2014;
Spinelli et al., 2019).
In general, the metaflammasome hypothesis is based on the
concept that dysfunction of the endoplasmic reticulum (due to
the accumulation of unfolded proteins) leads to the expanded
protein reaction and increased inflammation (Taga et al., 2017).
In addition, immunometabolic pathways are sensitive to
lipids and are associated with lipotoxicity, which in turn causes
metaflammation and changes in lipid metabolism (Ertunc and
Hotamisligil, 2016). Since insulin is an important regulator of
lipid metabolism as well, dyslipidemia is one of the main features
of IR. The characteristic of peripheral IR is an increased content
of free FAs (FFAs), an increase in the level of very-low-density
lipoprotein (VLDL), and a decrease in high-density lipoprotein
(HDL) (Kamagate et al., 2008; Neth and Craft, 2017). The
dyslipidemia plays a role in amyloid deposition in AD, probably
due to the effect of cholesterol on Aβ processing in the brain
(Berti et al., 2015; Neth and Craft, 2017). This was confirmed by
PET imaging. In addition, various genetic studies have identified
several genes involved in lipid and cholesterol metabolism as
increasing the risk of AD. This is primarily apolipoprotein-
E (ApoE), followed by apolipoprotein-J (APOJ or clusterin,
CLU), ATP-binding cassette subfamily A member 7 (ABCA7),
and sortilin-like receptor. These results suggest a potential link
between dyslipidemia and the accumulation of cerebral amyloid,
which, in turn, may be mediated by IR, as well as other causes of
lipid metabolism disorders, such as carriage of the Apoe4 allele
(Neth and Craft, 2017).
ApoE is the main apolipoprotein, produced in the CNS,
and directly increases the risk, progression, and pathogenesis
of AD. Allele differences in ApoE confer specific effects on
Aβ deposition, degradation and clearance, tau phosphorylation,
neuronal damage, and inflammation (Stukas et al., 2015). There
is evidence that the carriage of the ApoE4 allele can contribute
to a decrease in insulin signaling by directly interacting with
insulin receptors, leading to the uptake of insulin receptors
within endosomes (Zhao et al., 2017). The role of clusterin
(apolipoprotein J) in the risk and severity of AD was confirmed in
relation to both cognitive function and Aβ metabolism. ApoA-I
can also influence the pathology of AD, potentially by modulating
cerebrovascular integrity and function, aiding in the removal of
Aβ peptides from the cerebrovascular smooth muscle cells and
reducing inflammation (Stukas et al., 2015).
Anti-inflammatory Strategies Targeting
Neurodegeneration and Metaflammation
Since the important role of inflammation in the pathogenesis
of neurodegeneration and IR in various pathologies, including
diabetes mellitus and AD, has been convincingly shown,
approaches based on an anti-inflammatory strategy can be
used to treat symptoms and to interrupt the vicious circle
of metaflammation. As visceral fat is strongly linked to
metabolic disorders, strategies for correcting IR in metabolic-
cognitive states are very promising approaches as well
(Kullmann et al., 2020).
There is epidemiological evidence that some anti-
inflammatory approaches, in particular the use of non-steroidal
anti-inflammatory drugs (NSAIDs), reduce the risk of AD.
However, this category of drugs does not affect cognitive
function (Rivers-Auty et al., 2020). In clinical trials, no
evidence of the effectiveness of NSAIDs was found. The
ineffectiveness of anti-inflammatory strategies may be due
to inappropriate non-steroidal anti-inflammatory drugs or
due to epidemiological results caused by confounding factors.
However, there is evidence that, for example, the use of
diclofenac is associated with a decrease in morbidity, as well
as with a slower decline in cognitive function. However, this
requires further research into the potential therapeutic effects
Frontiers in Neuroscience | www.frontiersin.org 10 January 2021 | Volume 14 | Article 618395
fnins-14-618395 January 6, 2021 Time: 16:55 # 11
Komleva et al. Inflamm-Aging and Brain Insulin Resistance
of diclofenac in AD. Some antidiabetic drugs, which are aimed
at lowering blood sugar levels, also have anti-inflammatory
effects. This action is also associated with the hypolipidemic
effect and direct modulation of immune responses. Despite
promising results from clinical trials of anti-inflammatory
drugs, salicylates, no clear guidelines have been established
regarding the recommendation of these compounds for
the prevention or treatment of T2DM. The use of other
NSAIDs to combat metaflammation also requires clinical
trials. However, most of the known methods of treating
T2DM exhibit anti-inflammatory properties to varying degrees,
which arise because of triggering various pathways and
their effects, depending on many factors. Therefore, further
clinical studies are needed to test new drugs and identify
specific molecular pathways that could be therapeutically
targeting metainflammation (Kuryłowicz and Koźniewski, 2020;
Rivers-Auty et al., 2020).
There is evidence of a decrease in systemic inflammation with
the applying of dietary protocols in clinical trials, associated
primarily with a reduction in calorie intake (Lopez-Garcia
et al., 2004; Kuryłowicz and Koźniewski, 2020). High-fat diets
and high calories cause metainflammation, so the idea that
dietary intervention can help reduce inflammatory the response
in IR is very promising. Although the studies were not
uniform in design, all reported that weight loss, improved
glycemic control, and hepatic steatosis were associated with
varying degrees with serum C-reactive protein (CRP) reduction
(Kuryłowicz and Koźniewski, 2020).
Since it is a well-known fact that excess of nutrients in
the course of obesity and IR impairs metabolism leading to
the endoplasmic reticulum stress, possible CR may have a
protective role (Park et al., 2012; Kuryłowicz and Koźniewski,
2020; Ma et al., 2020).
Calorie restriction is one of the most promising approaches
for reducing the negative effects of metabolic disorders, age-
related diseases, and pathologies associated with metaflammation
(Park et al., 2012; Ma et al., 2020). In animal studies, it has
been shown that reducing calorie intake increases life span and
helps to lower blood glucose and insulin levels (Redman and
Ravussin, 2011; Kim et al., 2020). There is currently evidence
that CR for 2 years by 15% in healthy, non-obese people leads
to a decrease in systemic oxidative damage (Redman et al.,
2018). The main effects of CR in mammals include weight
loss, improved insulin signaling by increasing hormone receptor
sensitivity, normal lipid profiles, and increased adiponectin levels
(Balasubramanian et al., 2017).
Thus, research data demonstrate the beneficial effects of
CR in conditions such as diabetes, inflammation, obesity,
and cardiovascular disease (Redman et al., 2018). However,
the mechanisms underlying such changes remain unclear. An
increase in adipose tissue is associated with the development of
age-related metabolic changes, including the development of IR.
In contrast, a decrease in adipose tissue during prolonged CR
led to an improvement in age-related IR (Escrivá et al., 2007;
Fabbiano et al., 2016; Corrales et al., 2019). CR slows down
and restores age-related immunosenescence by regulating energy
metabolism and oxidative stress and decreasing the production
of proinflammatory cytokines and neuroendocrine homeostasis
(Costantini et al., 2018).
CALORIE RESTRICTION AND
COGNITIVE AND SOCIAL
DETERMINANTS OF AGING: CD38
SIGNALING MECHANISM IN AGING AND
NEURODEGENERATION
Inflammation, metainflammation, central and peripheral IR
are determinants of aging along with behavioral, social,
environmental, toxic, and other factors (Vidaček et al., 2018;
Lever-van Milligen et al., 2019; Epel, 2020) (Figure 4). Different
types of stressors can potentially lead to adaptive changes or
accelerated aging. It depends on the nature of the stressors, stress
resilience, and the stress response. At the same time, one of the
promising strategies of slowing aging is an increase in stress
resistance due to boosting stress resilience (Epel, 2020).
In relation to age and aging (pathological and physiological),
many intervention approaches are considered. There are many
potential approaches that may improve stress resilience: lifestyle
interventions and CR are thought to work in part through
adaptive response. Excess nutrients, high-fat diets, excessive
calorie intake, and the traditional American diet can act as a stress
acceleration of aging and lead to defective behavioral health.
Therefore, CR can be considered as a stress rejuvenescence.
The various effects of CR on metainflammation, IR, and
neurodegeneration have been described (Hotamisligil, 2017;
Epel, 2020). Less attention has been paid to the social
determinants of aging and the possible mechanism by which CR
might influence social behavior (Pifferi et al., 2018).
The positive effect of CR on cognitive longevity has been
described, including through the effect on the morphological
and functional properties of astroglia. Experiments on mice have
shown that CR increases astroglial complexity and improves
synaptic plasticity. Accordingly, this approach can increase
neural compensation and cognitive reserve contributing to the
healthy aging (Figure 4) (Verkhratsky et al., 2020).
One possible mechanism for mediated neuroprotection
of CR is by regulating Ng-associated Ca2+ signaling. It
causes a decrease in CaMKII and calpain activity, as well
as downstream signaling that regulates neuronal metabolism,
survival, and plasticity (Kim et al., 2016). CR significantly
enhances cerebral blood flow and BBB function in young mice
by reducing rapamycin expression, enhancing endothelial nitric
oxide synthase signaling, and increasing ketone body utilization.
This promotes memory formation and learning ability during
aging and reduces anxiety in aging mice (Parikh et al., 2016).
In a recent published study, the effect of CR on the social
brain function was determined. In the long-term study CALERIE
1, CR did not change mood, but CR enhanced mood in
patients in CALERIE 2, as well as improvements in tension
anxiety were detected (Dorling et al., 2020). At the same
time, there is also evidence that CR accelerated gray matter
atrophy in old mouse lemurs but protected old animals from
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FIGURE 4 | The metabolic pathway alteration in the development of metaflammation and inflamm-aging. Possible role of calorie restriction in preserving cognitive
reserve and social behavior. NLRP3, NLRP3 inflammasome; SASP, senescence-associated secretory phenotype.
white matter atrophy in comparison with old control animals
(Pifferi et al., 2018).
Currently, the mechanism of the CR influence on social
behavior remains relevant and unexplored. A potential
mechanism of this action may be the restoration of NAD+
through the activation of sirtuins and changes in the expression
of NADase-CD38 (Tarragó et al., 2018). It was revealed that
CD38 could act as a potential pharmacological target to reverse
age-related NAD+ decline. NAD+ is an energy metabolism
booster. CR affects AMP-activated protein kinase (AMPK)
activity, which can modulate the bioavailability of NAD+
(Connell et al., 2019).
Calorie restriction activates sirtuins, suppresses signaling
of growth hormone/insulin-like growth factors and mTORC1
(mammalian target of rapamycin), and enhances mitochondrial
redox regulation (Zullo et al., 2018). Sirtuins are a family of
proteins with NAD+-dependent enzymatic activities. Sirtuins
regulate various cellular processes including glucose production,
insulin sensitivity, inflammation, DNA repair, fat differentiation,
FA oxidation, neurogenesis, and aging (Lee et al., 2019).
Previous research has reported a link between sirtuins and
mitochondrial function and abnormal tau proteins and amyloid.
It was confirmed that SIRT1, 3, and 6 are involved in age-related
disease and regulation of life span, as well as AD progression
(Hoshino et al., 2018). In mice model of AD, accompanied by
impaired DNA repair, the precursor of NAD+, nicotinamide
riboside (NR), increases SIRT3 and SIRT6 (Hou et al., 2018). The
role of sirtuins has been proven not only in the development
of inflammation but also in IR. SIRT1 activation leads to the
suppression of metaflammasome components, namely, JNK and
IKK (Yoshizaki et al., 2010).
As already noted, neurons have a high-energy demand, and
therefore, they are very sensitive to a decrease in NAD+ and
disruption of ATP production. NAD+, by increasing the sirtuins,
affects neuronal survival, contributing to the maintenance of a
balance between mitochondrial biogenesis and mitophagy (Kerr
et al., 2017). These arguments are also supported by the fact
that selective overexpression of SIRT1 and SIRT6 in transgenic
mice increases the life span of animals. The application of
NAD+ precursors [NR, nicotinamide mononucleotide (NMN),
and nicotinamide] has a positive effect in neurodegenerative
diseases and aging. The restoration of the NAD+ level led to
an increase in life expectancy in different animal species (Zhang
et al., 2016; Hou et al., 2018). In this regard, it is logical to assume
that the restoration of NAD+ can act as a promising approach to
the treatment of AD by influencing the pathology of tau protein
and inflammation, as well as DNA repair (Hou et al., 2018).
Moreover, it is considered that NAD+ depletion not only is
characteristic of AD but also occurs during physiological aging;
the NAD+ precursor suppliers to medical nutrition leads to an
improvement in cognitive functions and synaptic plasticity in AD
(Gong et al., 2013). It is known that the enzymes involved in the
degradation of cellular NAD+ are CD38 and PARP. It is believed
that CD38 is the main NADase in mammalian tissues; in addition,
CD38 and its homolog BST-1/CD157 degrade both NMN and
NR. Thus, CD38 and BST-1 are involved in the regulation of
cell metabolism, regulation of sirtuin activity, and signaling. It
should be noted that genetic or pharmacological ablation of CD38
protects against metabolic dysfunction caused by a diet high in fat
and calories by modulating SIRT1 activity (Chini et al., 2017). The
studies in animals suggest that increasing tissue NAD+ levels by
genetic CD38 ablation can significantly alter energy homeostasis
in animals fed a calorie-excessive diet (Chiang et al., 2015).
At the same time, the physiological functions of CD38 in the
brain have also been established. Thus, CD38 has been shown
to play an important role in the secretion of oxytocin (OT)
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in the hypothalamus and in the regulation of social memory
and social interactions (Higashida et al., 2019). In addition,
recently, our group, together with Japanese colleagues, showed
that NR corrects social deficits, as well as anxious behavior in
CD157 knockout mice. These results suggest that increasing
NAD+ levels with NR may allow animals with a deficiency of
cyclic ADP-ribose and oxytocin to overcome this deficiency and
function normally (Gerasimenko et al., 2020). This is supported
by evidence that peripheral OXT administration improves social
recognition, object recognition, and depressive behavior in high-
fat-treated mice (Hayashi et al., 2020).
Therefore, diet-based strategies toward to CRs could be a
promising therapeutic approach against AD, by influencing
many signaling pathways, resulting in increasing cognitive
reserve and maintaining social function (Esposito et al.,
2015; Alkhatib et al., 2017; Wakabayashi et al., 2019;
Kuryłowicz and Koźniewski, 2020).
CONCLUSION
Thus, inflamm-aging is one of the manifestations immune
aging and is a risk factor of morbidity and mortality among
the elderly people. Since various chronic diseases associated
with age are directly associated with inflammatory response,
the approaches to decrease metaflammation could considered
as intervention in age-related pathology. Despite numerous
studies in age-associated pathologies, studies of the contribution
of the components of congenital immunity in healthy aging
are insufficient. It remains unclear whether the inflammatory
phenotype is a manifestation of healthy aging or is associated
with development age-related pathology. Moreover, given
the role of metainflammation in neurodegeneration, lifestyle
interventions such as CR may be an effective way to break
the vicious cycle of metainflammation and have a role in
social behavior.
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